ArticlePDF Available

Abstract

Chronic kidney disease has been observed to be a major threat to the world's health, and in some African countries, it is a death sentence. It affects economically productive young adults between the ages of 20-50 in Sub-Saharan Africa as against the middle age and elderly in the developed world. Challenges of renal care in Africa are numerous among which are equity, accessibility, financial constraint, and lack of workforce to mention a few. Therefore, Africa countries must prioritize renal care and include it in the health agenda to cater for the present and future health need of the people.
Saudi J Kidney Dis Transpl 2018;29(5):1188-1191
© 2018 Saudi Center for Organ Transplantation
Renal Data from AsiaAfrica
Chronic Kidney Disease in Sub-Saharan Africa
Samuel B. Ogundele
Department of Nursing, Afe Babalola University, Ado-Ekiti, Nigeria
ABSTRACT. Chronic kidney disease has been observed to be a major threat to the worlds
health, and in some African countries, it is a death sentence. It affects economically productive
young adults between the ages of 2050 in Sub-Saharan Africa as against the middle age and
elderly in the developed world. Challenges of renal care in Africa are numerous among which are
equity, accessibility, financial constraint, and lack of workforce to mention a few. Therefore,
Africa countries must prioritize renal care and include it in the health agenda to cater for the
present and future health need of the people.
Introduction
Africa is the second largest continent in the
world, and it accommodates 53 countries
hosting about one billion people.1Sub-Saharan
Africa (SSA) accounts for >80% of the land-
mass of the African continent with an esti-
mated population of 800 million. About 65%
of the population lives in rural settings, a
significant distance from cities where most of
the organized health-care delivery systems exist.2
Over a time, there has been a recent change
in the worlds disease profile and chronic
diseases are now becoming the leading cause
of morbidity and mortality in the world and
chronic kidney disease (CKD), which recently
has an increased prevalence in SSA, has been
Correspondence to:
Mr. Samuel B. Ogundele,
Department of Nursing, Afe Babalola
University, Ado-Ekiti, Nigeria.
E-mail: tosley2000@gmail.com
identified as one of the chronic diseases with
public health problem.3CKD is increasingly
recognized as a global public health problem
and a key determinant of the poor health
outcomes.4 Despite the global threat of CKD,
the scale of the problem is not fully appre-
ciated, especially in developing countries.
With an aging population, lifestyle changes
and rapid urbanization, the importance of non-
communicable diseases in the low- and middle-
income countries cannot be over emphasized.
It has been estimated that by 2030, >70% of
patients with end-stage renal disease will be
living in developing countries like SSA.5Lack
of kidney disease registry in SSA makes it
difficult to estimate the problem of CKD but
data from the United State of America suggest
that for every patient with end-stage renal
disease (ESRD) there are >200 with overt
CKD and almost 5000 with unknown renal
disease.2 Kidney disease impose a great human
suffering, and economic burden on African
continent and ESRD is projected to increase at
Saudi Journal
of Kidney Diseases
and Transplantation
[Downloaded free from http://www.sjkdt.org on Tuesday, October 30, 2018, IP: 93.167.71.26]
the rate of 6%8% in Africa.6
Risk Factors
Hypertension is an important worldwide public
health challenge because of its frequency and
associated risk of cardiovascular and kidney
disease,7 and it has been estimated that about
three-quarter of people living with hyper-
tension lives in developing world.8 Diabetes,
on the other hand, affect 2.8% of global popu-
lation in 2000 and this is estimated to triple to
6.8 by 2030 and by that time, 81% of those
with diabetes will be living in developing
countries.9 Africa is experiencing an accele-
rated increase in hypertension and diabetes
which are the underlying cause of CKD.6 HIV
associated nephropathy, acute kidney injury,
and CKD are some of the complication of HIV
infection and may become more pronounced
as patient live longer, especially in the era of
combined antiretroviral therapy.10 The rela-
tionship between intra-uterine factor and
development of CKD in adulthood has been
postulated but not well explored, for example,
low birth weight due to maternal nutritional
status and traditional herbal medicine is a
common issue among the disadvantaged popu-
lations, and it has been found to be associated
with kidney disease.11 More than 80% of the
population in SSA is estimated to use herbal or
traditional medicines which are thought to
have been associated with 35% of all new
cases of acute kidney injury.5
Renal Replacement Therapy in Sub-
Saharan Africa
Renal replacement therapy (RRT) which is
the treatment of choice is expensive, and it
contributes a heavy burden on the healthy
system even in wealthy countries. RRT for
kidney failure includes hemodialysis (HD),
peritoneal dialysis (PD), and renal transplant.
In Africa, in-center HD is the most common
modality, PD is seldom used because of the
cost of importing fluids whereas only seven
countries in SSA offer renal transplant to their
patient and it is mostly living donor transplant.1
There is increased prevalence of ESRD in
Africa and access to RRT is often expensive
and usually unavailable.12 Over 3.3 million
people have been estimated to be receiving
RRT globally, and majority of the patient are
treated in developed world, for example, more
than half of the population of patients on
dialysis are treated in just five countries (USA,
China, Japan, Brazil and Mexico).13 A global
study conducted in 2010, have shown that
Africa has a high disparity between demand
and supply of RRT.12
Government provides financial support for
patients on HD in some African countries such
as South Africa, Malawi, Sudan, Tanzania,
and Nigeria,13 but the reverse is the case in
other countries for example a study conducted
in Nigeria shows that <1% of patients can
afford treatment for more than three months
mainly because of financial constraint.12
Globally, the cost of dialysis care ranges from
USD $100 and $200, but in some countries in
SSA, it ranges from USD $80 to $160, USD
$130 to $200, USD $10 to $120, USD $50 to
$100, USD $70 to $110, and USD $120 in
South Africa, Uganda, Cameroon, Kenya,
Ethiopia, and Nigeria, respectively.13 PD is
still at its infancy stage in most countries in
SSA and kidney transplant is also available in
few countries such as South Africa, Sudan,
Nigeria, Kenya, Mauritius, and Cameroon.13,14
Out of 47 countries in SSA, only 6.3% have a
functioning renal transplant program2and the
cost of renal transplant in SSA ranges between
$3,000 and $20,000.13
In Africa like the rest of the world, the need
for renal care and RRT is on the increase, but
only a few countries can meet the need of their
citizen.1 The number of people requiring RRT
globally was estimated to be 4.99 million and
only 2.6 million people are on dialysis which
suggests that at least 2.3 million died pre-
maturely because of lack of access to RRT.4In
Asia and Africa, people receiving RRT are
likely to double from 2010 to 2030, and the
number of people without access to RRT is
projected to increase concurrently.12 CKD is a
progressive disease which jeopardizes survival
and quality of life but can be managed thera-
CKD in sub-Saharan Africa 1189
[Downloaded free from http://www.sjkdt.org on Tuesday, October 30, 2018, IP: 93.167.71.26]
peutically by RRT.15 In developing world
ESRD is a death sentence to a lot of people
because RRT is often unavailable or unaffor-
dable.16 Considering the problem of hyper-
tension, diabetes, obesity, and HIV/AIDS in
SSA, it is expected that population in need
RRT over the next few years will increase
drastically. Renal care in Africa is quite
challenging and is in a critical stage as there is
a short supply of health workers across the
board coupled with heavy financial burden of
RRT. Nephrologists are scarce in Africa
generally, but this is likely to get worse
because there is serious migration of health
care professionals across the board and this
has created a great threat to the public health
system in the region.
Summary
Economic burden of CKD is enormous and
can be in the form of direct loss of gross
domestic product, losses due to household
financing of care, consumption pattern, and
financial cost of managing the disease.11
Africa as a continent may be sitting on a keg
of gunpowder unknowingly and therefore must
reconsider how she views this silent killer.
Preventive measures have been recognized as
a key strategy in the management of CKD, but
it is still in its infancy stage in most Africa
country which is mainly due to lack of
workforce and funding.
Conclusion
There is need to establish CKD screening
center/clinic in all primary health care centers
and not as a standalone program but rather
incorporated into the already established pro-
gram for other chronic diseases. To overcome
this burden, there is a need for competent
workforce, therefore, the government need to
focus on training and retention of more
nephrologists and nephrology nurses. It is of a
truth that we cannot appreciate the extent of
this problem until we have a good record
system. Therefore, a district database should
be established to capture patient diagnosed
with kidney disease, and a proper channel
must be established for the referral system and
follow-up. The government should look for-
ward to developing policies and strategies to
increase the number of RRT centers available
in other to prepare for the potential need for
RRT.
Conflict of interest: None declared.
References
1. Naicker S. End-stage renal disease in Sub-
Saharan Africa. Kidney Int Suppl 2013;3:161-
3.
2. Pozo ME, Leow JJ, Groen RS, Kamara TB,
Hardy MA, Kushner AL. An overview of renal
replacement therapy and health care personnel
deficiencies in sub-Saharan Africa. Transpl Int
2012;25:652-7.
3. Yirsaw BD. Chronic kidney disease in Sub-
Saharan Africa: Hypothesis for research
demand. Ann Afr Med 2012;11:119-20.
4. Garcia-garcia G, Jha V. Chronic kidney
disease (CKD) in disadvantaged populations.
Clin Kidney J 2015;8:3-6.
5. Stanifer JW, Jing B, Tolan S, et al. The epide-
miology of chronic kidney disease in Sub-
Saharan Africa: A systematic review and meta-
analysis. Lancet Glob Health 2014;2:e174-81.
6. Ojo A. Addressing the global burden of
chronic kidney disease through clinical and
translational research. Trans Am Clin Climatol
Assoc 2014;125:229-43.
7. Seedat YK. Control of hypertension in South
Africa: Time for action. S Afr Med J 2011;
102:25-6.
8. Ibrahim MM, Damasceno A. Hypertension in
developing countries. Lancet 2012;380:611-9.
9. Remuzzi G. The global burden of chronic
kidney diseases waits for better renoprotection.
Arch Med Sci 2009;5:S393-4.
10. Flandre P, Pugliese P, Cuzin L, et al. Risk
factors of chronic kidney disease in HIV-
infected patients. Clin J Am Soc Nephrol
2011;6:1700-7.
11. Jha V, Wang AY, Wang H. The impact of
CKD identification in large countries: The
burden of illness. Nephrol Dial Transplant
2012;27 Suppl 3:iii32-8.
12. Okpechi IG. ESKD in Sub-Saharan Africa: Will
governments now listen? Lancet Glob Health
2017;5:e373-4.
1190 Ogundele SB
[Downloaded free from http://www.sjkdt.org on Tuesday, October 30, 2018, IP: 93.167.71.26]
13. Bamgboye EL. The challenges of ESRD care
in developing economies: Sub-Saharan African
opportunities for significant improvement. Clin
Nephrol 2016;86:18-22.
14. Anand S, Bitton A, Gaziano T. The gap
between estimated incidence of end-stage renal
disease and use of therapy. PLoS One 2013;8:
e72860.
15. Vanholder R, Van Biesen W, Lameire N. Renal
replacement therapy: How can we contain the
costs? Lancet 2014;383:1783-5.
16. Couser WG, Remuzzi G, Mendis S, Tonelli M.
The contribution of chronic kidney disease to
the global burden of major noncommunicable
diseases. Kidney Int 2011;80:1258-70.
Date of manuscript receipt: 10 June 2017.
Date of revised copy receipt:15 July 2017.
Date of final acceptance: 16 July 2017.
CKD in sub-Saharan Africa 1191
[Downloaded free from http://www.sjkdt.org on Tuesday, October 30, 2018, IP: 93.167.71.26]
... The socio-demographic characteristics of in this study might not be unconnected to the study area where most of the working population both in private and public sector are male. Though, Naicker (2013) and Ogundele (2018) infer that CKD usually affects adult between the ages of 20-50, this study's high burden in the same age category accounts for 71% of the total cases reported here. Also in this regard, both Naicker (2013) and Ogundele (2018) reporting on end-stage renal disease in Sub-Saharan Africa (SSA) concur by suggesting that disease conditions such as hypertension and glomerular diseases. ...
... Though, Naicker (2013) and Ogundele (2018) infer that CKD usually affects adult between the ages of 20-50, this study's high burden in the same age category accounts for 71% of the total cases reported here. Also in this regard, both Naicker (2013) and Ogundele (2018) reporting on end-stage renal disease in Sub-Saharan Africa (SSA) concur by suggesting that disease conditions such as hypertension and glomerular diseases. However, Ogundele (2018) further suggests that use of traditional herbal medicines by disadvantaged populations in SSA is often associated with cases of kidney diseases. ...
... Also in this regard, both Naicker (2013) and Ogundele (2018) reporting on end-stage renal disease in Sub-Saharan Africa (SSA) concur by suggesting that disease conditions such as hypertension and glomerular diseases. However, Ogundele (2018) further suggests that use of traditional herbal medicines by disadvantaged populations in SSA is often associated with cases of kidney diseases. ...
Article
Full-text available
Purpose: The study was conducted to examine the trend of chronic kidney disease (CKD) in as seen at Rasheed Shekoni Teaching Hospital (RSTH), Dutse, a state referral centre for CKD cases in Jigawa state over a six-year period from January 2015 to December 2020. Methods: Retrospective research design was used where all the 621 cases seen in the facility over the study period were retrieved and reviewed. Ethical clearance was obtained from the Research and Ethics Committee of RSTH. Data was analysed using frequency tables, charts and multiple regression analysis. Results: The result revealed the mean age of the cases as 39±1 and 62% were males. While the CKD burden between 2016 (51) and 2016 (47) were relatively lower than the later years, a marked increase in the number of CKD cases was witnessed in the facility in 2017 (147) and the curve plateaued at such high prevalence through 2018 (155) and 2019 (151) until 2020 where a drastic drop (70) was witnessed were only 11.2% of the cases were seen. Conclusion: The findings further revealed having chronic glomerulonephritis, comorbidities of hypertension and chronic glomerulonephritis and, hypertension and diabetes, being 60 years & above and being male (p<0.05) as the predictors of having CKD among the patients seen at the facility. It was concluded that, there is a growing trend in the burden of CKD in the state and there is need for further investigations to determine the factors behind it in order to proffer solution to the problem.
... The socio-demographic characteristics of in this study might not be unconnected to the study area where most of the working population both in private and public sector are male. Though, Naicker (2013) and Ogundele (2018) infer that CKD usually affects adult between the ages of 20-50, this study's high burden in the same age category accounts for 71% of the total cases reported here. Also in this regard, both Naicker (2013) and Ogundele (2018) reporting on end-stage renal disease in Sub-Saharan Africa (SSA) concur by suggesting that disease conditions such as hypertension and glomerular diseases. ...
... Though, Naicker (2013) and Ogundele (2018) infer that CKD usually affects adult between the ages of 20-50, this study's high burden in the same age category accounts for 71% of the total cases reported here. Also in this regard, both Naicker (2013) and Ogundele (2018) reporting on end-stage renal disease in Sub-Saharan Africa (SSA) concur by suggesting that disease conditions such as hypertension and glomerular diseases. However, Ogundele (2018) further suggests that use of traditional herbal medicines by disadvantaged populations in SSA is often associated with cases of kidney diseases. ...
... Also in this regard, both Naicker (2013) and Ogundele (2018) reporting on end-stage renal disease in Sub-Saharan Africa (SSA) concur by suggesting that disease conditions such as hypertension and glomerular diseases. However, Ogundele (2018) further suggests that use of traditional herbal medicines by disadvantaged populations in SSA is often associated with cases of kidney diseases. ...
Article
Full-text available
p> Purpose : The study was conducted to examine the trend of chronic kidney disease (CKD) in as seen at Rasheed Shekoni Teaching Hospital (RSTH), Dutse, a state referral centre for CKD cases in Jigawa state over a six-year period from January 2015 to December 2020. Methods : Retrospective research design was used where all the 621 cases seen in the facility over the study period were retrieved and reviewed. Ethical clearance was obtained from the Research and Ethics Committee of RSTH. Data was analysed using frequency tables, charts and multiple regression analysis. Results : The result revealed the mean age of the cases as 39±1 and 62% were males. While the CKD burden between 2016 (51) and 2016 (47) were relatively lower than the later years, a marked increase in the number of CKD cases was witnessed in the facility in 2017 (147) and the curve plateaued at such high prevalence through 2018 (155) and 2019 (151) until 2020 where a drastic drop (70) was witnessed were only 11.2% of the cases were seen. Conclusion : The findings further revealed having chronic glomerulonephritis, comorbidities of hypertension and chronic glomerulonephritis and, hypertension and diabetes, being 60 years & above and being male (p<0.05) as the predictors of having CKD among the patients seen at the facility. It was concluded that, there is a growing trend in the burden of CKD in the state and there is need for further investigations to determine the factors behind it in order to proffer solution to the problem. </p
... If left untreated, the kidney can malfunction, leading to kidney failure and the need for dialysis or kidney transplants, 84,85 but such kidney disease treatments and management are difficult to come by in resource-limited countries. 32,86 The present review also attempted to conduct a subgroup analysis based on sub-region, gender, publication year, and diabetes type. MAU had the highest pooled prevalence of 46.50% (95% CI: 32.29-60.71) in studies conducted in Northern Africa, 48 [42][43][44][45]59,62,66,67 This disparity could be attributed to differences in study subjects, urine collection methods, the presence of comorbidity, and assay methods used in those African countries. ...
Article
Full-text available
Background Microalbuminuria (MAU) is considered the earliest sign of diabetic nephropathy among diabetes patients. In order to effectively manage diabetic nephropathy and its consequences early, detection of microalbuminuria as soon as possible, especially for diabetes patients, is critical. Therefore, the present study aimed to determine the pooled prevalence of microalbuminuria among diabetes patients in Africa. Methods Electronic databases such as Google Scholar, PubMed, African Journals Online, Web of Science, Cochrane Library, EMBASE, and ResearchGate were searched for articles and grey literature. The STATA version 14 software was used to conduct the meta-analysis. I² and Cochran’s Q test were employed to assess the presence of heterogeneity between studies. Due to the presence of heterogeneity, a random effect model was used. The publication bias was assessed using the symmetry of the funnel plot and Egger’s test statistics. Moreover, subgroup analysis, trim and fill analysis, and sensitivity analysis were also done. Results The overall pooled prevalence of microalbuminuria among diabetes patients in Africa was 37.11% (95% CI 31.27–42.95). Substantial heterogeneity was observed between studies, with I² values of 94.7%. Moreover, this meta-analysis showed that the pooled estimate of microalbuminuria among type 1 and type 2 diabetes patients was 35.34% (95% CI: 23.89–46.80, I²=94.2), and 40.24% (95% CI: 32.0–48.47, I²=94.9) respectively. MAU, on the other hand, was more common in people with diabetes for more than 5 years 38.73% (95% CI: 29.34–48.13) than in people with diabetes for less than 5 years 31.48% (95% CI: 18.73–44.23). Conclusion This systematic review and meta-analysis found a high prevalence of microalbuminuria among diabetes patients. As a result, early detection of microalbuminuria is critical for preventing and treating microvascular complications such as diabetic nephropathy and the onset of end-stage renal disease.
... 9,10 In these low-resource settings, end-stage renal disease is often a death sentence for a lot of people since renal replacement therapy is often unavailable or unaffordable. 11 The global increase in CKD is linked to its leading causes, mainly, diabetes mellitus (DM) and hypertension, and risk factors like family history of CKD, aging, and HIV/AIDS. 12,13 Although a nationwide estimate of CKD is not available in Ethiopia, the rise in the leading causes (hypertension and DM), epidemiological transition, and increasing urbanization 9,10 necessitates studying the prevalence of CKD and its predictors in Ethiopia. ...
Article
Full-text available
Objective: This study aimed to assess the magnitude of chronic kidney disease among patients attending the renal unit of St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. Methods: Institution-based cross-sectional study was conducted among 620 randomly selected patients who visited St. Paul's Hospital Millennium Medical College renal unit from 1 January to 31 December, 2019. Data on sociodemographic characteristics, clinical conditions, behavioral risk factors, electrolytes, and renal function tests were extracted from patients' medical records. To enter and analyze data, EpiData 3.1 and SPSS 22 were used, respectively. Bivariable and multivariable logistic regression analyses were conducted to see the association between predictor variables and chronic kidney disease. Adjusted odds ratio at 95% confidence interval was used to describe significant association. A p-value <0.05 was considered to declare an association between chronic kidney disease and independent variables. Results: Of 620 patients, 139 (22.4%; 95% confidence interval: 19.2, 25.6) and 61 (9.8%; 95% confidence interval: 7.4, 12.3) had chronic kidney disease using cut-off value of 90 and 60 ml/min/1.73 m2, respectively. Having urinary tract obstruction (adjusted odds ratio = 2.32; 95% confidence interval: 1.32, 4.06), hypertension (adjusted odds ratio = 4.06; 95% confidence interval: 2.50, 6.59), diabetes mellitus (adjusted odds ratio = 2.80; 95% confidence interval: 1.62, 4.85), cardiovascular disease (adjusted odds ratio = 2.54; 95% confidence interval: 1.60, 4.01), and age (adjusted odds ratio = 1.83; 95% confidence interval: 1.44, 3.57), family history of chronic kidney disease (adjusted odds ratio = 2.26; 95% confidence interval: 1.36, 3.75) were factors positively associated with having chronic kidney disease. Conclusion: Nearly, one out of five and one out of ten patients who visited the renal unit had chronic kidney disease using the two thresholds as a cut value. Patients with concomitant urinary tract obstruction, age, hypertension, diabetes mellitus, cardiovascular disease, and a family history of chronic kidney disease were more likely to develop chronic kidney disease. Regular screening for chronic kidney disease, optimal blood sugar, and blood pressure management should be practiced.
... Oxidative renal injury has been implicated in the pathogenesis and progression of kidney disease and kidney failure if not properly managed (Barnett and Cummings, 2018;Ratliff et al., 2016). The economic burden of the disease has been reported and attributed to its costs of treatment and management, especially in sub-Saharan Africa with poor basic health facilities (Foley and Collins, 2009;Ogundele, 2018;Wang et al., 2016). Thus, the continuous search for cheaper and affordable treatments. ...
Article
Ethnopharmacological relevance: Cannabis sativa L. is among numerous medicinal plants widely used in traditional medicine in treating various ailments including kidney diseases. Aims: The protective effect of C. sativa on oxidative stress, cholinergic and purinergic dysfunctions, and dysregulated glucogenic activities were investigated in oxidative injured kidney (Vero) cell lines. Methods: Fixed Vero cells were treated with sequential extracts (hexane, dichloromethane [DCM] and ethanol) of C. sativa leaves for 48 h before subjecting to MTT assay. Vero cells were further incubated with FeSO4 for 30 minutes, following pretreatment with C. sativa extracts for 25 minutes. Normal control consisted of Vero cells not treated with the extracts and/or FeSO4, while untreated (negative) control consisted of cells treated with only FeSO4. Results: MTT assay revealed the extracts were slightly cytotoxic at the highest concentrations (250 μg/mL). There was a significant depletion in glutathione level and catalase activity on induction of oxidative stress, with significant elevation in malondialdehyde level, acetylcholinesterase, ATPase, ENTPDase, fructose-1,6-biphosphatase, glucose 6-phosphatase and glycogen phosphorylase activities. These activities and levels were significantly reversed following pretreatment with C. sativa extracts. Conclusion: These results portray the protective potentials of C. sativa against iron-mediated oxidative renal injury as depicted by the ability of its extracts to mitigate redox imbalance and suppress acetylcholinestererase activity, while concomitantly modulating purinergic and glucogenic enzymes activities in Vero cells.
... While DM is the commonest cause of CKD in the western world, [4,44,45] it is the third leading cause of CKD in Nigeria. [11,[46][47][48] Diabetic nephropathy in its earliest stages is asymptomatic with the initial clinically detectable stage presenting with microalbuminuria and hypertension. Our study was not designed to evaluate the contribution of diabetic nephropathy to reduced eGFR in these patients. ...
Article
Full-text available
Background: Hypertension is one of the commonest cause of chronic kidney disease (CKD) in Nigerians. We describe blood pressure (BP) control and kidney disease markers in patients with hypertension as part of measures to curb the burden of this chronic debilitating disease. Methods: Patients with hypertension in the main tertiary hospitals in three states in north central Nigeria were evaluated for indicators of CKD, including proteinuria and estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2. Patients had their early morning first void urine tested for proteinuria using Combi-10 test strips. eGFR was estimated using the MDRD equation. Results: A total of 1063 subjects (63.1% females and 36.8% males) with a mean age of 55 ± 11 years were studied. Diabetes mellitus (DM) was present in 214 (20.6%) and 422 (39.7%) had optimal BP control. The median duration of hypertension was 6 years (range 1-44 years). Proteinuria occurred in 130 (12.2%), while 212 (19.9%) had reduced eGFR and 46 (4.3%) had proteinuria and reduced eGFR. The use of calcium channel blockers [adjusted odds ratio (AOR): 0.70, 95% Confidence Interval (CI) 0.50-0.99] and the use of more than two antihypertensive medications (AOR: 0.62, 95% CI 0.40-0.96) were associated with reduced odds of optimal BP control. Male sex (AOR: 1.75, 95% CI 1.14-2.70) and the use of renin-angiotensin-aldosterone system blocking medications (AOR: 2.07, 95% CI 1.18-3.64) were independently associated with proteinuria while DM (AOR: 1.69, 95% CI 1.06-2.55) and treatment with more than two medications (AOR: 1.86, 95% CI 1.09-3.17) were more likely to have reduced eGFR. Conclusion: A large proportion of hypertensive patients in north-central Nigeria have poorly controlled BP. Kidney damage is common among these patients.
... The future risk of NCD forms of CKD, predominantly driven by increased rates of hypertension, is a growing public health concern in Ghana [ [6][7][8][9], and in some African countries, it is a death sentence [20]. Although the epidemiology of CKD in Africa is well elucidated to some extent [21], current evidence has uncovered new approaches to understanding the pathogenesis of CKD [11]. ...
Article
Full-text available
Background Chronic kidney disease (CKD) is a significant comorbidity among hypertensive patients. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) have been demonstrated to be significantly associated with CKD, among African- and European-derived populations. We investigated the spectrum of MYH9-associated CKD among Ghanaian hypertensive patients. Methods The study constituted a total of 264 hypertensive patients. Hypertensive patients with glomerular filtration rate (eGFR) < 60 ml/min/1.73m ² (CKD-EPI formula) or clinically diagnosed were defined as case subjects ( n = 132) while those with eGFR ≥60 ml/min/1.73m ² were classified as control subjects ( n = 132). Demographic data were obtained with a questionnaire and anthropometric measurements were taken. Five (5) millilitres (ml) of venous blood was drawn from study subjects into gel and EDTA vacutainer tubes. Two (2) mL of EDTA anticoagulated blood was used for genomic DNA extraction while three (3) mL of blood was processed to obtain serum for biochemical measurements. Genotyping of MYH9 polymorphisms (rs3752462) was done employing Tetra primer Amplification Refractory Mutation System (T-ARMS) polymerase chain reaction (PCR). Spot urine samples were also collected for urinalysis. Hardy-Weinberg population was assessed. Logistic regression models were used to assess the associations between single nucleotide polymorphisms and CKD. Results The cases and control participants differed in terms of age, sex, family history, and duration of CKD ( p -value < 0.001). The minor allele frequencies of rs3752462 SNP were 0.820 and 0.567 respectively among the control and case subjects. Patients with the heterozygote genotype of rs3752462 (CT) were more likely to develop CKD [aOR = 7.82 (3.81–16.04)] whereas those with homozygote recessive variant (TT) were protective [aOR = 0.12 (0.06–0.25)]. Single nucleotide polymorphism of rs3752462 (CT genotype) was associated with increased proteinuria, albuminuria, and reduced eGFR. Conclusions We have demonstrated that MYH9 polymorphisms exist among Ghanaian hypertensive patients and rs3752462 polymorphism of MYH9 is associated with CKD. This baseline indicates that further longitudinal and multi-institutional studies in larger cohorts in Ghana are warranted to evaluate MYH9 SNP as an independent predictor of CKD among hypertensive patients in Ghana.
Article
Full-text available
Chronic kidney disease (CKD), a global public health problem, is increasing at an alarming rate across Africa. The increasing CKD burden in this region is mainly driven by a rapid surge in the prevalence of risk factors including diabetes, hypertension, obesity, and infectious diseases. To further aggravate the situation, CKD is known to progress rapidly to kidney failure (KF) in patients of African ethnicity. Given the serious health implications and prohibitively expensive treatment, it is paramount to focus on novel therapeutic prospects in CKD management to delay its progression to KF, prevent complications, and prolong survival. In recent years, substantial clinical and real-world evidence confirmed the cardiorenal protective benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with CKD, with or without diabetes. In this context, a steering committee meeting was convened with 13 key experts from the African Association of Nephrology (AFRAN) to discuss the epidemiology and magnitude of region specific CKD burden, unmet needs and challenges, and implications of SGLT2i use in CKD management. This paper summarizes the expert views and opinions on the applicability of SGLT2is in different populations with CKD to support their safe implementation in clinical practice with a focus on reducing the CKD burden in the region.
Article
Full-text available
Chronic kidney disease (CKD) is becoming a major public health issue worldwide and an important contributor to the overall non-communicable disease burden. It is associated with major serious consequences including increased risk of mortality, end-stage renal disease, accelerated cardiovascular disease (CVD), mineral and bone disease, adverse metabolic and nutritional consequences, infections, reduced cognitive function and increased risk of acute kidney injury. Mortality from CVD is estimated to be at least 8- to 10-fold higher in CKD subjects compared to non-CKD subjects. Estimates from different parts of the world, especially large countries, reveal an increasing incidence and prevalence of CKD. This is partly attributed to the global increasing prevalence of diabetes, hypertension, obesity and CVD. The global economic impact of CKD is tremendous. This calls for the need of a global effort to raise awareness of CKD, to incorporate prevention of CKD progression program in the public health agenda and to implement programs for early screening and detection of CKD, especially in high-risk population so to allow early institution of treatment to prevent further CKD progression. Hopefully, by doing so, we may reduce CKD burden globally over time and, most importantly, improve the health outcomes of patients with CKD.
Article
Full-text available
Twelve March 2015 will mark the 10th anniversary of World Kidney Day (WKD), an initiative of the International Society of Nephrology and the International Federation of Kidney Foundations. Since its inception in 2006, WKD has become the most successful effort ever mounted to raise awareness among decision-makers and the general public about the importance of kidney disease. Each year WKD reminds us that kidney disease is common, harmful and treatable. The focus of WKD 2015 is on chronic kidney disease (CKD) in disadvantaged populations. This article reviews the key links between poverty and CKD and the consequent implications for the prevention of kidney disease and the care of kidney patients in these populations.
Article
Full-text available
Background: Amid rapid urbanisation, the HIV epidemic, and increasing rates of non-communicable diseases, people in sub-Saharan Africa are especially vulnerable to kidney disease. Little is known about the epidemiology of chronic kidney disease (CKD) in sub-Saharan Africa, so we did a systematic review and meta-analysis examining the epidemiology of the disease. Methods: We searched Medline, Embase, and WHO Global Health Library databases for all articles published through March 29, 2012, and searched the reference lists of retrieved articles. We independently reviewed each study for quality. We used the inverse-variance random-effects method for meta-analyses of the medium-quality and high-quality data and explored heterogeneity by comparing CKD burdens across countries, settings (urban or rural), comorbid disorders (hypertension, diabetes, HIV), CKD definitions, and time. Findings: Overall, we included 90 studies from 96 sites in the review. Study quality was low, with only 18 (20%) medium-quality studies and three (3%) high-quality studies. We noted moderate heterogeneity between the medium-quality and high-quality studies (n=21; I2=47·11%, p
Article
Full-text available
Relatively few data exist on the burden of end-stage renal disease (ESRD) and use of renal replacement therapy (RRT)-a life-saving therapy-in developing regions. No study has quantified the proportion of patients who develop ESRD but are unable to access RRT. We performed a comprehensive literature search to estimate use and annual initiation of RRT worldwide, and present these estimates according to World Bank regions. We also present estimates of survival and of etiology of diseases in patients undergoing RRT. Using data on prevalence of diabetes and hypertension, we modeled the incidence of ESRD related to these risk factors in order to quantify the gap between ESRD and use of RRT in developing regions. We find that 1.9 million patients are undergoing RRT worldwide, with continued use and annual initiation at 316 and 73 per million population respectively. RRT use correlates directly (Pearson's r = 0.94) with regional income. Hemodialysis remains the dominant form of RRT but there is wide regional variation in its use. With the exception of the Latin American and Caribbean region, it appears that initiation of RRT in developing regions is restricted to fewer than a quarter of patients projected to develop ESRD. This results in at least 1.2 million premature deaths each year due to lack of access to RRT as a result of diabetes and elevated blood pressure and as many as 3.2 million premature deaths due to all causes of ESRD. Thus, the majority of patients projected to reach ESRD due to diabetes or hypertension in developing regions are unable to access RRT; this gap will increase with rising prevalence of these risk factors worldwide.
Article
Chronic kidney disease (CKD) is a significant cause of morbidity and mortality in sub-Saharan Africa. This, along with other noncommunicable diseases like hypertension, diabetes, and heart diseases, poses a double burden on a region that is still struggling to cope with the scourge of communicable diseases like malaria, tuberculosis, HIV, and more recently Ebola. Causes of CKD in the region are predominantly glomerulonephritis and hypertension, although type 2 diabetes is also becoming a significant cause as is the retroviral disease. Patients are generally younger than in the developed world, and there is a significant male preponderance. Most patients are managed by hemodialysis, with peritoneal dialysis and kidney transplantation being available in only few countries in the region. Government funding and support for dialysis is often unavailable, and when available, often with restrictions. There is a dearth of trained manpower to treat the disease, and many countries have a limited number of units, which are often ill-equipped to deal adequately with the number of patients who require end-stage renal disease (ESRD) care in the region. Although there has been a significant improvement when compared with the situation, even as recently as 10 years ago, there is also the potential for further improvement, which would significantly improve the outcomes in patients with ESRD in the region. The information in this review was obtained from a combination of renal registry reports (published and unpublished), published articles, responses to a questionnaire sent to nephrologists prior to the World Congress of Nephrology (WCN) in Cape Town, and from nephrologists attending the WCN in Cape Town (March 13 - 17, 2015).
Article
Worldwide, an estimated 200 million people have chronic kidney disease (CKD). In the United States, African Americans (AAs) have a four-fold excess risk of CKD compared to non-Hispanic white people and globally, people in the low-to-middle income countries of Asia and Sub-Saharan Africa have the highest rates of CKD. Annually, more than 500,000 individuals develop end-stage renal disease (or CKD stage 5) in Sub-Saharan Africa alone and the vast majority of these patients suffer premature mortality. The health care costs and economic burden of CKD are huge and not sustainable even in advanced Western countries. A recent discovery on the role of Apolipoprotein 1 (APOL1) G1 and G2 renal risk variants in AAs has a huge potential to unravel the etiology of CKD in both AA and other black populations. Under the National Institutes of Health (NIH)-sponsored Human Heredity and Health in Africa (H3Africa) initiative, a large prospective genetic study of CKD is being conducted in 8000 participants in four African countries (Ethiopia, Ghana, Kenya, and Nigeria; for a total population of 320 million). This and other basic research studies in the United States could potentially shed great insight into the genetics and biologic mechanisms involved in the excess predilection of Africans and AAs to CKD.